

Association of Azithromycin With Mortality and Cardio Patients Hospitalized With Pneumonia

JAMA - Journal of the American Medical Association

311, 2199

DOI: [10.1001/jama.2014.4304](https://doi.org/10.1001/jama.2014.4304)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Î²-Lactam Monotherapy vs Î²-Lactamâ€“Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia. JAMA Internal Medicine, 2014, 174, 1894.	2.6	203
2	Azithromycin for Elderly Patients With Pneumonia. JAMA - Journal of the American Medical Association, 2014, 312, 1352.	3.8	0
3	The Debate on Antibiotic Therapy for Patients Hospitalized for Pneumonia. JAMA Internal Medicine, 2014, 174, 1901.	2.6	5
4	The cardiovascular safety of azithromycin. Cmaj, 2014, 186, 1127-1128.	0.9	15
5	Community-Acquired Pneumonia. New England Journal of Medicine, 2014, 371, 1619-1628.	13.9	486
6	Azithromycin associated with a reduction in 90-day mortality among older pneumonia patients, although a true clinical benefit is uncertain. Evidence-Based Medicine, 2014, 19, 226-227.	0.6	2
7	Macrolide Antibiotics for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations: Are We There Yet?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1-2.	2.5	10
8	Infectiologie respiratoire. Revue Des Maladies Respiratoires Actualites, 2015, 7, S48-S53.	0.0	0
9	Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment. BMC Infectious Diseases, 2015, 15, 380.	1.3	14
10	Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. Pharmacoepidemiology and Drug Safety, 2015, 24, 1042-1048.	0.9	19
11	Current status and inspiration on macrolides in the treatment of chronic obstructive pulmonary disease. Journal of Translational Internal Medicine, 2015, 3, 85-88.	1.0	0
12	Azithromycin and Risk of Cardiovascular Death. American Journal of Therapeutics, 2015, 22, e122-e129.	0.5	21
13	The bacterial pneumonias: a new treatment paradigm. Hospital Practice (1995), 2015, 43, 46-55.	0.5	3
14	Cardiovascular Risks Associated With Azithromycin: Worth the Hype?. Journal for Nurse Practitioners, 2015, 11, 149-150.	0.4	0
15	Treatment of community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2015, 13, 1109-1121.	2.0	4
16	Cardiotoxicity during Invasive Pneumococcal Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 739-745.	2.5	70
17	Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respiratory Investigation, 2015, 53, 178-184.	0.9	61
18	Cardiovascular Complications in Community-acquired Pneumonia. Clinical Pulmonary Medicine, 2015, 22, 62-67.	0.3	3

#	ARTICLE	IF	CITATIONS
19	Chromogranin A levels and mortality in patients with severe sepsis. <i>Biomarkers</i> , 2015, 20, 171-176.	0.9	8
20	Pneumonies aiguës communautaires: peut-on encore en améliorer le pronostic?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 227-237.	0.0	0
21	Community-acquired pneumonia. <i>Lancet, The</i> , 2015, 386, 1097-1108.	6.3	392
22	Miscellaneous Antibacterial Drugs. <i>Side Effects of Drugs Annual</i> , 2015, , 293-305.	0.6	0
23	The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia. <i>Current Infectious Disease Reports</i> , 2015, 17, 50.	1.3	6
24	Editorial Commentary:The Mismatch Between Physicians' Expectations and Microbiologic Reality. <i>Clinical Infectious Diseases</i> , 2015, 61, 1411-1412.	2.9	1
25	Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly. <i>American Journal of Medicine</i> , 2015, 128, 1362.e1-1362.e6.	0.6	35
26	Significant publications on infectious diseases pharmacotherapy in 2014. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1380-1392.	0.5	8
27	Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. <i>Respiratory Investigation</i> , 2015, 53, 201-209.	0.9	27
28	The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2173-2184.	1.2	130
29	Risks of Cardiac Arrhythmia and Mortality Among Patients Using New-Generation Macrolides, Fluoroquinolones, and β -Lactam/ β -Lactamase Inhibitors: A Taiwanese Nationwide Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 566-577.	2.9	71
30	Cardiac risks associated with antibiotics: azithromycin and levofloxacin. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 295-303.	1.0	61
31	The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. <i>Clinical Microbiology and Infection</i> , 2015, 21, 20-26.	2.8	43
32	Advances in the prevention, management, and treatment of community-acquired pneumonia. <i>F1000Research</i> , 2016, 5, 300.	0.8	26
33	Ronda clínica y epidemiológica: club de revistas. <i>Iatreia</i> , 2016, 29, .	0.1	0
34	Lessons learned from 2 decades of CAP therapy data: ways to improve patient management. <i>Journal of Thoracic Disease</i> , 2016, 8, E455-E459.	0.6	1
35	Macrolide therapy of pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 212-217.	1.3	11
36	Improving outcomes in community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 235-242.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Cardiovascular disease as a complication of community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 212-218.	1.2	56
38	Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. <i>Infection and Immunity</i> , 2016, 84, 1457-1469.	1.0	71
39	Clinical management of community acquired pneumonia in the elderly patient. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1211-1220.	1.0	25
40	Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes. <i>Journal of Critical Care</i> , 2016, 36, 265-271.	1.0	19
41	Controversies in the Management of Community-Acquired Pneumonia. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 126-135.	0.6	0
42	Regional variation in antibiotic prescribing among medicare part D enrollees, 2013. <i>BMC Infectious Diseases</i> , 2016, 16, 744.	1.3	31
43	Impact of the FDA Warning for Azithromycin and Risk for QT Prolongation on Utilization at an Academic Medical Center. <i>Hospital Pharmacy</i> , 2016, 51, 830-833.	0.4	7
44	Association of macrolides with overall mortality and cardiac death among patients with various infections: A meta-analysis. <i>European Journal of Internal Medicine</i> , 2016, 28, 32-37.	1.0	10
45	Evaluation of baseline corrected QT interval and azithromycin prescriptions in an academic medical center. <i>Journal of Hospital Medicine</i> , 2016, 11, 15-20.	0.7	16
46	Community-Acquired Pneumonia in Patients With Diabetes Mellitus: Predictors of Complications and Length of Hospital Stay. <i>American Journal of the Medical Sciences</i> , 2016, 352, 30-35.	0.4	11
47	Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 593.	3.8	115
48	Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. <i>Cmaj</i> , 2016, 188, E120-E129.	0.9	109
49	Bacterial Pneumonia and Lung Abscess. , 2016, , 557-582.e22.		6
50	Is cardiovascular risk a concern when prescribing azithromycin?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2017, 30, 11-13.	0.1	5
51	Use of azithromycin and risk of ventricular arrhythmia. <i>Cmaj</i> , 2017, 189, E560-E568.	0.9	42
52	Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2017, 40, 663-677.	1.4	34
53	Antimicrobials and QT prolongation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1272-1274.	1.3	43
54	Cardiac Arrest in Pediatric Patients Receiving Azithromycin. <i>Journal of Pediatrics</i> , 2017, 182, 311-314.e1.	0.9	3

#	ARTICLE	IF	CITATIONS
55	Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. <i>Antiviral Research</i> , 2017, 144, 48-56.	1.9	75
56	Pharmacotherapy for community-acquired pneumonia in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 957-964.	0.9	11
57	Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 147-155.	1.0	19
58	Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients. <i>Clinical Microbiology and Infection</i> , 2017, 23, 774.e1-774.e7.	2.8	5
59	Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric <i>Pseudomonas</i> Therapy. <i>Pharmacotherapy</i> , 2017, 37, 195-203.	1.2	2
60	Appraisal of the cardiovascular risks of azithromycin: an observational analysis. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 509-517.	0.6	4
61	Macrolide resistance mechanisms in <i>Enterobacteriaceae</i> : Focus on azithromycin. <i>Critical Reviews in Microbiology</i> , 2017, 43, 1-30.	2.7	104
62	Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up. <i>BMJ: British Medical Journal</i> , 2017, 356, j413.	2.4	65
63	Controversies in diagnosis and management of community-acquired pneumonia. <i>Medical Journal of Australia</i> , 2017, 206, 316-319.	0.8	4
64	Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	28
65	Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	49
66	Pneumonia as a cardiovascular disease. <i>Respirology</i> , 2018, 23, 250-259.	1.3	87
67	The Association Between Major Depressive Disorder and Outcomes in Older Veterans Hospitalized With Pneumonia. <i>American Journal of the Medical Sciences</i> , 2018, 355, 21-26.	0.4	10
68	Inappropriate Use of Antimicrobials for Lower Respiratory Tract Infections in Elderly Patients: Patient- and Community-Related Implications and Possible Interventions. <i>Drugs and Aging</i> , 2018, 35, 389-398.	1.3	7
69	The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 50-63.	2.7	49
70	QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. <i>Psychosomatics</i> , 2018, 59, 105-122.	2.5	116
71	Adjunctive Therapies for Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 753-764.	0.8	9
72	2018 recommendations for the management of community acquired pneumonia. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 405-423.	0.4	33

#	ARTICLE	IF	CITATIONS
73	Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. <i>International Journal of COPD</i> , 2018, Volume 13, 3813-3829.	0.9	44
74	Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2018, 122, 1809-1816.	0.7	4
75	Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases. <i>Respiratory Care</i> , 2018, 63, 671-689.	0.8	15
76	Pharmacological Therapy of COPD. <i>Chest</i> , 2018, 154, 1404-1415.	0.4	19
77	Clinical Approach to Community-acquired Pneumonia. <i>Journal of Thoracic Imaging</i> , 2018, 33, 273-281.	0.8	11
78	Treating bacterial pneumonia in people living with HIV. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 771-786.	1.0	4
79	Hot topics and current controversies in community-acquired pneumonia. <i>Breathe</i> , 2019, 15, 216-225.	0.6	16
80	Impact of Cirrhosis on Pneumonia-Related Outcomes in Hospitalized Older Veterans. <i>American Journal of the Medical Sciences</i> , 2019, 357, 296-301.	0.4	6
81	The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , 2019, 39, 718-723.	1.2	7
82	Duration and life-stage of antibiotic use and risk of cardiovascular events in women. <i>European Heart Journal</i> , 2019, 40, 3838-3845.	1.0	32
83	Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort study. <i>American Journal of Infection Control</i> , 2019, 47, 1053-1058.	1.1	5
84	Association of atypical antipsychotics and mortality for patients hospitalised with pneumonia. <i>ERJ Open Research</i> , 2019, 5, 00223-2018.	1.1	14
85	Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2019, 12, e005691.	1.6	7
86	Severe Community-Acquired Pneumonia. , 2019, , .		2
87	Effect of Combined β -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2019, 155, 795-804.	0.4	34
88	Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial. <i>BMC Infectious Diseases</i> , 2019, 19, 17.	1.3	29
89	Electrocardiographic Effects of a Supratherapeutic Dose of $\langle \text{WCK} \rangle$ 2349, a Benzoquinolizine Fluoroquinolone. <i>Clinical and Translational Science</i> , 2019, 12, 47-52.	1.5	10
90	Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1894-1900.	0.4	10

#	ARTICLE	IF	CITATIONS
91	Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality. <i>Circulation Research</i> , 2020, 126, 364-373.	2.0	28
92	Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. <i>Drug Safety</i> , 2020, 43, 691-698.	1.4	102
93	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. <i>Pharmacotherapy</i> , 2020, 40, 978-983.	1.2	4
94	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. <i>Journal of Electrocardiology</i> , 2020, 62, 59-64.	0.4	17
95	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020, 56, 1-10.	0.4	34
96	Azithromycin prophylaxis after lung transplantation is associated with improved overall survival. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1426-1434.	0.3	19
97	Tetrodotoxin-sensitive Neuronal Type Na ⁺ Channels: A Novel and Druggable Target for Prevention of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e015119.	1.6	5
98	Association of Azithromycin Use With Cardiovascular Mortality. <i>JAMA Network Open</i> , 2020, 3, e208199.	2.8	30
99	Considerations for the optimal management of antibiotic therapy in elderly patients. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 325-333.	0.9	27
100	Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. <i>Advances in Therapy</i> , 2020, 37, 1302-1318.	1.3	100
101	Preventing the development of severe COVID-19 by modifying immunothrombosis. <i>Life Sciences</i> , 2021, 264, 118617.	2.0	40
102	The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. <i>Clinical and Translational Science</i> , 2021, 14, 106-112.	1.5	2
103	Azithromycin in the treatment of COVID-19: a review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 147-163.	2.0	167
104	Antibiotic Therapy Associated Cardiotoxicity. <i>International Healthcare Research Journal</i> , 2021, 4, RV18-RV21.	0.0	0
105	Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS). <i>Drugs - Real World Outcomes</i> , 2021, 8, 131-140.	0.7	7
106	The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating biomarkers for renal function, hepatic function and electrical properties of the heart. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 959-963.	1.0	3
107	Short-Course Azithromycin for Lower Respiratory Tract Infection in Adults. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e140-e145.	0.1	0
108	Antiviral Activity of Azithromycin (A Synthetic Macrolide) for Next Step of COVID-19. <i>Asian Journal of Chemistry</i> , 2021, 33, 1594-1602.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Acute cardiovascular events in patients with community acquired pneumonia: results from the observational prospective FADOI-ICECAP study. BMC Infectious Diseases, 2021, 21, 116.	1.3	10
110	Macrolide therapy for patients with pneumonia: a triple-edged sword. , 0, , 206-231.		1
111	Cardiovascular side-effects of common antibiotics. , 2020, , 264-278.		1
112	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLoS ONE, 2017, 12, e0178022.	1.1	25
113	Treatment options for community-acquired pneumonia in the elderly people. Expert Review of Anti-Infective Therapy, 2015, 13, 473-85.	2.0	8
114	Pharmaceutical Care Approach to Treating Pneumonia among the Elderly with Intravenous Azithromycin. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016, 42, 634-644.	0.0	1
115	A review of macrolide based regimens for community-acquired pneumonia.. The University of Louisville Journal of Respiratory Infections, 2017, 1, .	0.2	0
117	Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections. , 2020, , 212-228.		0
118	Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia. Clinical Infectious Diseases, 2022, 75, 118-124.	2.9	8
119	Medication Safety in Chronic Lung Disease with Cardiac Comorbidity. Respiratory Medicine, 2020, , 161-212.	0.1	0
121	Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Medical Research Methodology, 2021, 21, 241.	1.4	117
122	Severe community-acquired pneumonia. , 0, , 101-116.		0
123	Antibiotics for pulmonary infections: an overview. , 0, , 1-20.		0
124	Antibiotic stewardship in the community. , 0, , 111-126.		0
125	Long-term oral antibiotic treatment: why, what, when and to whom?. , 0, , 185-205.		0
126	Comorbidities and their impact. , 0, , 45-61.		1
127	Antibiotic stewardship in the hospital setting. , 0, , 127-149.		0
128	Prophylactic antibiotics. , 0, , 197-212.		0

#	ARTICLE	IF	CITATIONS
129	Comparative safety of inhaled corticosteroids and macrolides in Medicare enrollees with bronchiectasis. ERJ Open Research, 2022, 8, 00786-2020.	1.1	6
130	Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data. Fundamental and Clinical Pharmacology, 2022, 36, 1099-1105.	1.0	7
131	The Acute Effects of Azithromycin Use on Cardiovascular Mortality as Compared with Amoxicillin-Clavulanate in United States Veterans. Pharmacoepidemiology and Drug Safety, 2022, , .	0.9	0
132	Magnitude of Coagulation Abnormalities and Associated Factors Among Patients with Heart Diseases at the University of Gondar Comprehensive Specialized Hospital. Vascular Health and Risk Management, 0, Volume 18, 617-627.	1.0	2
133	Perfil de Segurança e Eficácia Clínica da Azitromicina no Tratamento da COVID-19: Revisão da Literatura. Archives of Health Investigation, 2022, 11, 332-336.	0.0	0
134	Guideline-Concordant Antibiotic Therapy for the Hospital Treatment of Community-Acquired Pneumonia and 1-Year All-Cause and Cardiovascular Mortality in Older Adult Patients Surviving to Discharge. Chest, 2023, 163, 1380-1389.	0.4	2
137	Safety and Tolerability of Antimicrobial Agents in the Older Patient. Drugs and Aging, 2023, 40, 499-526.	1.3	6
138	ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Medicine, 2023, 49, 615-632.	3.9	41
139	ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. European Respiratory Journal, 2023, 61, 2200735.	3.1	22
146	Toxicity consideration of antibiotics. , 2023, , 297-328.		0